HomeCompareNMMRF vs ABBV

NMMRF vs ABBV: Dividend Comparison 2026

NMMRF yields 4.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMMRF wins by $13.6K in total portfolio value· pulled ahead in Year 8
10 years
NMMRF
NMMRF
● Live price
4.58%
Share price
$1,008.35
Annual div
$46.23
5Y div CAGR
34.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$116.0K
Annual income
$36,450.05
Full NMMRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NMMRF vs ABBV

📍 NMMRF pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMMRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMMRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMMRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMMRF
Annual income on $10K today (after 15% tax)
$389.70/yr
After 10yr DRIP, annual income (after tax)
$30,982.54/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NMMRF beats the other by $9,926.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMMRF + ABBV for your $10,000?

NMMRF: 50%ABBV: 50%
100% ABBV50/50100% NMMRF
Portfolio after 10yr
$109.2K
Annual income
$30,610.90/yr
Blended yield
28.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NMMRF
No analyst data
Altman Z
1.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMMRF buys
0
ABBV buys
0
No recent congressional trades found for NMMRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMMRFABBV
Forward yield4.58%3.06%
Annual dividend / share$46.23$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR34.7%40.6%
Portfolio after 10y$116.0K$102.3K
Annual income after 10y$36,450.05$24,771.77
Total dividends collected$86.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NMMRF vs ABBV ($10,000, DRIP)

YearNMMRF PortfolioNMMRF Income/yrABBV PortfolioABBV Income/yrGap
1$11,318$617.56$11,550$430.00$232.00ABBV
2$12,990$879.87$13,472$627.96$482.00ABBV
3$15,170$1,271.29$15,906$926.08$736.00ABBV
4$18,101$1,869.06$19,071$1,382.55$970.00ABBV
5$22,176$2,807.52$23,302$2,095.81$1.1KABBV
6$28,058$4,329.91$29,150$3,237.93$1.1KABBV
7$36,919$6,896.68$37,536$5,121.41$617.00ABBV
8← crossover$50,927$11,423.89$50,079$8,338.38+$848.00NMMRF
9$74,330$19,838.03$69,753$14,065.80+$4.6KNMMRF
10$115,983$36,450.05$102,337$24,771.77+$13.6KNMMRF

NMMRF vs ABBV: Complete Analysis 2026

NMMRFStock

Nomura Real Estate Master Fund,Inc. is a real estate investment trust (REIT) company. It aims to achieve sustainable growth in asset and stable earnings from mid-term to long-term perspectives. The Fund mainly invests in commercial buildings and logistic facilities located in the Tokyo area, Kinki area and other regions. The Fund manager is Nomura Real Estate Asset Management Co., Ltd.

Full NMMRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NMMRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMMRF vs SCHDNMMRF vs JEPINMMRF vs ONMMRF vs KONMMRF vs MAINNMMRF vs JNJNMMRF vs MRKNMMRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.